person · Reporting owner

Hutton Scott

Disclosed activity across 2 companies

Tapewire entity: 65186
SEC CIK: 0001697361

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIODESIX INCBDSX · Entity 6053	Director · President & CEO	February 20, 2026	February 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date February 20, 2026 · Filed February 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,767	Ending reported balance After 2026-02-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-20 · Exercise / conversion · Acquired 4,844 · Balance 50,257 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 1,490 · Balance 48,767 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	14,531	Reported balance After 2026-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-20 · Exercise / conversion · Disposed 4,844 · Balance 14,531 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SPECTRANETICS CORP

Report date August 09, 2017 · Filed August 11, 2017

Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Righ to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.85 · Expires 2027-01-31	Direct	Reported balance After 2017-08-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-08-09 · Disposition to issuer · Disposed 8,464 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement"), each stock option that was outstanding and unexercised as of immediately prior to the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the number of shares of Company common stock for which such stock option had not then been exercised and (ii) the excess, if any, of the 38.50 per share in cash over the exercise price per share of Company common stock subject to each such stock option, without interest and less any required withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2017-08-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-08-09 · Disposition to issuer · Disposed 15,473 · Balance 0 F2: Per the terms of the Merger Agreement, each restricted stock unit award that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash in amount equal to $38.50 per share in cash, without interest and less any required withholding taxes.
Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2017-08-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-08-09 · Disposition to issuer · Disposed 7,736 · Balance 0 F3: Per the terms of the Merger Agreement, each performance stock unit granted in 2017 that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash equal to the product of (i) the number of shares of Company common stock subject to such performance stock units (assuming that any applicable performance conditions were deemed to be achieved at the target performance level) and (ii) $38.50, without interest and less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement"), each stock option that was outstanding and unexercised as of immediately prior to the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the number of shares of Company common stock for which such stock option had not then been exercised and (ii) the excess, if any, of the 38.50 per share in cash over the exercise price per share of Company common stock subject to each such stock option, without interest and less any required withholding taxes.

F2: Per the terms of the Merger Agreement, each restricted stock unit award that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash in amount equal to $38.50 per share in cash, without interest and less any required withholding taxes.

F3: Per the terms of the Merger Agreement, each performance stock unit granted in 2017 that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash equal to the product of (i) the number of shares of Company common stock subject to such performance stock units (assuming that any applicable performance conditions were deemed to be achieved at the target performance level) and (ii) $38.50, without interest and less any required withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 23, 2026 Filed Feb 23, 2026 20:22 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	1,490	$12.78	$19,035.64	Disclosure SEC source: 0000905148-26-000988 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,767 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 20, 2026 Filed Feb 23, 2026 20:22 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	4,844	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000988 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,531 Underlying: Common Stock · 4,844 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F4 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document
February 20, 2026 Filed Feb 23, 2026 20:22 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	4,844	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-000988 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
February 10, 2026 Filed Feb 11, 2026 18:03 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	3,559	$10.08	$35,889.31	Disclosure SEC source: 0000905148-26-000633 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,413 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 09, 2026 Filed Feb 11, 2026 18:03 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	9,388	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000633 · form4.xml · derivative · entry 4 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,388 Underlying: Common Stock · 9,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F6 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document
February 09, 2026 Filed Feb 11, 2026 18:03 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	610	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000633 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. F4 · derivative.expiration_date: These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. Read SEC document
February 09, 2026 Filed Feb 11, 2026 18:03 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	9,998	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-000633 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
January 16, 2026 Filed Jan 20, 2026 16:21 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	970	$8.15	$7,904.82	Disclosure SEC source: 0000905148-26-000250 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,974 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 15, 2026 Filed Jan 20, 2026 16:21 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	2,633	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000250 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,265 Underlying: Common Stock · 2,633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F4 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document
January 15, 2026 Filed Jan 20, 2026 16:21 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	2,633	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-000250 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
January 02, 2026 Filed Jan 6, 2026 16:25 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	97,000	$0.00 Strike: $6.46	$0.00	Disclosure SEC source: 0000905148-26-000066 · form4.xml · derivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 97,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: This option vests in a series of forty-eight successive, substantially equal monthly installments measured from January 2, 2026, generally subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document
November 10, 2025 Filed Nov 13, 2025 16:53 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	611	$0.00	$0.00	Disclosure SEC source: 0000905148-25-003930 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610 Underlying: Common Stock · 611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split"). F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split"). F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split"). Read SEC document
November 10, 2025 Filed Nov 13, 2025 16:53 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	189	$7.62	$1,440.18	Disclosure SEC source: 0000905148-25-003930 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,311 F4 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. Read SEC document
November 10, 2025 Filed Nov 13, 2025 16:53 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	611	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-003930 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split"). F2 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split"). F3 · balance_after: Includes 448 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025. Read SEC document
August 13, 2025 Filed Aug 14, 2025 17:25 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	3,772	$0.42	$1,570.28	Disclosure SEC source: 0000905148-25-002983 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,824 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.4076 to $0.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 12, 2025 Filed Aug 14, 2025 17:25 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-25-002983 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,424 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
August 12, 2025 Filed Aug 14, 2025 17:25 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	12,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-002983 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 13, 2025 Filed May 13, 2025 18:35 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	1,887	$0.35	$665.92	Disclosure SEC source: 0000905148-25-001606 · form4.xml · nonDerivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,384 F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.3395 to $0.3622, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 12, 2025 Filed May 13, 2025 18:35 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	1,888	$0.36	$678.55	Disclosure SEC source: 0000905148-25-001606 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,271 F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.3431 to $0.4014, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 09, 2025 Filed May 13, 2025 18:35 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-25-001606 · form4.xml · derivative · entry 4 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,636 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
May 09, 2025 Filed May 13, 2025 18:35 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	12,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-001606 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 10,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2025. Read SEC document
February 20, 2025 Filed Feb 26, 2025 16:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	425,929	$0.00 Strike: $0.92	$0.00	Disclosure SEC source: 0000905148-25-000779 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,929 Underlying: Common Stock · 425,929 shares Expires 2035-02-19 F4 · derivative.exercise_date: This option vested in full on February 20, 2025. Under the Issuer's 2024 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2024 in the form of a fully-vested option. Read SEC document
February 20, 2025 Filed Feb 26, 2025 16:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	775,000	$0.00 Strike: $0.92	$0.00	Disclosure SEC source: 0000905148-25-000779 · form4.xml · derivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775,000 Underlying: Common Stock · 775,000 shares Expires 2035-02-19 F3 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from February 20, 2025, generally subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
February 20, 2025 Filed Feb 26, 2025 16:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	387,500	$0.00	$0.00	Disclosure SEC source: 0000905148-25-000779 · form4.xml · derivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,500 Underlying: Common Stock · 387,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
February 11, 2025 Filed Feb 12, 2025 17:11 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	83,660	$0.92	$77,318.57	Disclosure SEC source: 0000905148-25-000525 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 701,947 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.9536, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 10, 2025 Filed Feb 12, 2025 17:11 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	52,656	$0.00	$0.00	Disclosure SEC source: 0000905148-25-000525 · form4.xml · derivative · entry 5 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,969 Underlying: Common Stock · 52,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
February 10, 2025 Filed Feb 12, 2025 17:11 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	187,760	$0.00	$0.00	Disclosure SEC source: 0000905148-25-000525 · form4.xml · derivative · entry 4 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,521 Underlying: Common Stock · 187,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
February 10, 2025 Filed Feb 12, 2025 17:11 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-25-000525 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,848 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
February 10, 2025 Filed Feb 12, 2025 17:11 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	252,628	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-000525 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 785,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
November 12, 2024 Filed Nov 13, 2024 16:21 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	1,813	$1.40	$2,539.65	Disclosure SEC source: 0000905148-24-003056 · form4.xml · nonDerivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,979 F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 11, 2024 Filed Nov 13, 2024 16:21 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	1,927	$1.39	$2,680.26	Disclosure SEC source: 0000905148-24-003056 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,792 F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.36 to $1.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 08, 2024 Filed Nov 13, 2024 16:21 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-24-003056 · form4.xml · derivative · entry 4 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,060 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
November 08, 2024 Filed Nov 13, 2024 16:21 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	12,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-003056 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 6,139 shares purchased under the Issuer's Employee Stock Purchase Plan on August 30, 2024. Read SEC document
August 12, 2024 Filed Aug 12, 2024 19:23 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	963	$1.57	$1,513.74	Disclosure SEC source: 0000905148-24-002113 · form4.xml · nonDerivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,368 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.52 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 09, 2024 Filed Aug 12, 2024 19:23 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	2,781	$1.60	$4,452.38	Disclosure SEC source: 0000905148-24-002113 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,331 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 08, 2024 Filed Aug 12, 2024 19:23 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-24-002113 · form4.xml · derivative · entry 4 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,272 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
August 08, 2024 Filed Aug 12, 2024 19:23 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	12,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-002113 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 23, 2024 Filed May 23, 2024 19:13 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionSeries A Non-Voting Convertible Preferred Stock · Derivative	653	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001608 · form4.xml · derivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.exercise_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.expiration_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. Read SEC document
May 23, 2024 Filed May 23, 2024 19:13 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	26,120	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-001608 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. Read SEC document
May 09, 2024 Filed May 10, 2024 17:04 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	3,764	$1.48	$5,568.84	Disclosure SEC source: 0000905148-24-001352 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,780 F4 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 08, 2024 Filed May 10, 2024 17:04 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001352 · form4.xml · derivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,484 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
May 08, 2024 Filed May 10, 2024 17:04 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	12,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-001352 · form4.xml · nonDerivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes an aggregate 321 shares that were inadvertently reported as being sold on February 9 and February 12, 2024 in the Form 4 filed by the Reporting Person on February 12, 2024. F3 · balance_after: Includes 10,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 29, 2024. Read SEC document
April 05, 2024 Filed Apr 9, 2024 19:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantSeries A Non-Voting Convertible Preferred Stock · Derivative	653	$46.00	$30,038.00	Disclosure SEC source: 0000905148-24-001137 · form4.xml · derivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 653 Underlying: Common Stock · 26,120 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. Read SEC document
February 21, 2024 Filed Feb 29, 2024 18:15 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	180,926	$0.00 Strike: $1.46	$0.00	Disclosure SEC source: 0000905148-24-000823 · form4.xml · derivative · entry 1 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,926 Underlying: Common Stock · 180,926 shares Expires 2034-02-20 F1 · derivative.exercise_date: This option vested in full on February 21, 2024. Under the Issuer's 2023 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2023 in the form of a fully-vested option. Read SEC document
February 12, 2024 Filed Feb 12, 2024 21:45 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	29,708	$1.66	$49,454.91	Disclosure SEC source: 0000905148-24-000584 · form4.xml · nonDerivative · entry 3 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,011 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 09, 2024 Filed Feb 12, 2024 21:45 UTC	BIODESIX INC BDSX · Entity 6053	SaleCommon Stock	34,682	$1.92	$66,471.52	Disclosure SEC source: 0000905148-24-000584 · form4.xml · nonDerivative · entry 2 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,719 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.8191 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 08, 2024 Filed Feb 12, 2024 21:45 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	187,761	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000584 · form4.xml · derivative · entry 7 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,281 Underlying: Common Stock · 187,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F8 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
February 08, 2024 Filed Feb 12, 2024 21:45 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	12,212	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000584 · form4.xml · derivative · entry 6 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,696 Underlying: Common Stock · 12,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F7 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
February 08, 2024 Filed Feb 12, 2024 21:45 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	421,250	$0.00 Strike: $1.99	$0.00	Disclosure SEC source: 0000905148-24-000584 · form4.xml · derivative · entry 5 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,250 Underlying: Common Stock · 421,250 shares Expires 2034-02-07 F6 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from January 15, 2024, generally subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
February 08, 2024 Filed Feb 12, 2024 21:45 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	210,625	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000584 · form4.xml · derivative · entry 4 Hutton Scott · CIK 0001697361 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,625 Underlying: Common Stock · 210,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.